Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

CryptoAlerta — análise de criptomoedas e mercado em tempo real